Statera BioPharma (STU:7CB) EBIT : €-17.49 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma EBIT?

Statera BioPharma's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2022 was €-1.56 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2022 was €-17.49 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Statera BioPharma's annualized ROC % for the quarter that ended in Sep. 2022 was -30.96%. Statera BioPharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -565.32%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Statera BioPharma EBIT Historical Data

The historical data trend for Statera BioPharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma EBIT Chart

Statera BioPharma Annual Data

Trend

Dec19

Dec20

Dec21

EBIT

-2.53

-8.97

-25.95

Statera BioPharma Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EBIT	Get a 7-Day Free Trial						-8.20	-7.22	-6.01	-2.70	-1.56

Competitive Comparison of Statera BioPharma's EBIT

For the Biotechnology subindustry, Statera BioPharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's EV-to-EBIT falls into.

Statera BioPharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.49 Mil.

Statera BioPharma (STU:7CB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Statera BioPharma's annualized ROC % for the quarter that ended in Sep. 2022 is calculated as:

	ROC % (Q: Sep. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2022 )	+	Invested Capital (Q: Sep. 2022 ))	/ count )
=	-5.928 * ( 1 - 0% )	/	( (18.786	+	19.509)	/ 2 )
=	-5.928	/	19.1475
=	-30.96 %

where

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	12.811	-	11.047	-	( 0.678	-	max(0, 18.608	-	1.586	+	0.678	))
=	18.786

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	12.876	-	14.586	-	( 0.511	-	max(0, 22.453	-	1.234	+	0.511	))
=	19.509

Note: The Operating Income data used here is four times the quarterly (Sep. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Statera BioPharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2022		Q: Sep. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-6.244	/	( ( (1.178 + max(-11.491, 0))	+	(1.031 + max(-15.123, 0)) )	/	2 )
=	-6.244	/	( ( 1.178	+	1.031 )	/	2 )
=	-6.244	/	1.1045
=	-565.32 %

where Working Capital is:

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.206	+	0	+	0.515)	-	(11.047	+	0.52	+	0.645)
=	-11.491

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.185	+	0	+	0.358)	-	(14.586	+	0.391	+	0.689)
=	-15.123

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Statera BioPharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2022 )
	=	-17.485	/	0.000
	=	%

Statera BioPharma EBIT Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Statera BioPharma (STU:7CB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (STU:7CB) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525

Website

https://www.staterabiopharma.com

Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Statera BioPharma (STU:7CB) Headlines

No Headlines